Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2Gastrointestinal 1Dermatologic 1

Conditions

Non-Melanoma Skin Carcinoma 1

Interventions

pembrolizumab 181Nivolumab 117Ipilimumab 97Dacarbazine 48trametinib 37dabrafenib 353-ingenyl angelate 35Vemurafenib 33cemiplimab 27atezolizumab 24Temozolomide 24binimetinib 23Paclitaxel 22Imiquimod 22encorafenib 17avelumab 17Carboplatin 17Aminolevulinic Acid 17spartalizumab 16cobimetinib 16Cyclophosphamide 15Cisplatin 15Fluorouracil 14talimogene laherparepvec 13HhAntag691 11Gels 11Drug Therapy 11Bevacizumab 11lenvatinib 10durvalumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Voriconazole × Dermatologic × Clear all
NCT01480219 2013-03-11

Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009g

Pfizer

Completed
467 enrolled 6 charts
Dermatologic

Non-Melanoma Skin Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡